Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -353.00% is 298% below its 5-year average of -88.79%, near the high end of its 5-year range (-4375.16%–29.35%).
228.14% below its 12-month average of -107.58%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
-353.00%
NET PROFIT MARGIN AVG TTM
-107.58%
NET PROFIT MARGIN AVG 3Y
-16.01%
NET PROFIT MARGIN AVG 5Y
-88.79%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-228.14%
CURRENT VS 3Y AVG
-2104.22%
CURRENT VS 5Y AVG
-297.57%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Korsana Biosciences, Inc.
Market Cap
$144.19M
Net Profit Margin
-353.00%
TTM Avg
-107.58%
3Y Avg
-16.01%
5Y Avg
-88.79%
Market Cap
$143.60M
Net Profit Margin
-435.70%
TTM Avg
-1104.64%
3Y Avg
-1053.90%
5Y Avg
-4200.61%
Market Cap
$143.21M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-3984.32%
5Y Avg
-3047.80%
Market Cap
$145.90M
Net Profit Margin
-10.40%
TTM Avg
-6.28%
3Y Avg
-16.07%
5Y Avg
-47.85%
Market Cap
$148.77M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$139.63M
Net Profit Margin
-153.61%
TTM Avg
-101.12%
3Y Avg
-50.56%
5Y Avg
-33.71%
Market Cap
$148.43M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-85.02%
Market Cap
$139.73M
Net Profit Margin
163.32%
TTM Avg
-34.49%
3Y Avg
-63.76%
5Y Avg
-75.19%
Market Cap
$149.20M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Korsana Biosciences, Inc. (KRSA) | $144.19M | -353.00% | -107.58% | -16.01% | -88.79% |
| Nyxoah S.A. (NYXH)vs › | $143.60M | -435.70% | -1104.64% | -1053.90% | -4200.61% |
| Immuneering Corporation (IMRX)vs › | $143.21M | 0.00% | 0.00% | -3984.32% | -3047.80% |
| LifeMD, Inc. (LFMDP)vs › | $145.90M | -10.40% | -6.28% | -16.07% | -47.85% |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $148.77M | 0.00% | 0.00% | 0.00% | 0.00% |
| Alpha Cognition Inc (ACOG)vs › | $139.63M | -153.61% | -101.12% | -50.56% | -33.71% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $148.43M | 0.00% | 0.00% | 0.00% | -85.02% |
| Fortress Biotech, Inc. (FBIOP)vs › | $139.73M | 163.32% | -34.49% | -63.76% | -75.19% |
| Anavex Life Sciences Corp. (AVXL)vs › | $149.20M | 0.00% | 0.00% | 0.00% | 0.00% |
| Codexis, Inc. (CDXS)vs › | $151.12M | -39.55% | -86.23% | -76.35% | -60.08% |
Operating Margin
-239.8%
Net Profit Margin
-353.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | -77.95% |
| 2025-09-30 | -111.54% |
| 2025-06-30 | -348.39% |
| 2025-03-31 | -1764.20% |
| 2024-12-31 | 29.35% |
| 2024-09-30 | -372.68% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | -4375.16% |
| 2022-03-31 | -1825.32% |
| 2021-12-31 | -2021.58% |
| 2021-09-30 | -3244.25% |
| 2021-06-30 | -539.40% |
| 2021-03-31 | -21611.29% |
| 2020-12-31 | -14457.14% |
| 2020-09-30 | -4703.00% |
| 2020-06-30 | -2608.01% |
| 2020-03-31 | -1994.87% |
| 2019-12-31 | -1759.28% |
| 2019-09-30 | -1954.01% |
| 2019-06-30 | -1981.20% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
